{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Tafreshi NK"],"funding":["National Cancer Institute","NCI NIH HHS","Neuroendocrine Tumor Research Foundation","H. Lee Moffitt Cancer Center and Research Institute"],"pagination":["3408-3421"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC12866175"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["48(11)"],"pubmed_abstract":["<h4>Purpose</h4>There is significant interest in the development of targeted alpha-particle therapies (TATs) for treatment of solid tumors. The metal chelator-peptide conjugate, DOTA-TATE, loaded with the β-particle emitting radionuclide <sup>177</sup>Lu ([<sup>177</sup>Lu]Lu-DOTA-TATE) is now standard care for neuroendocrine tumors that express the somatostatin receptor 2 (SSTR2) target. A recent clinical study demonstrated efficacy of the corresponding [<sup>225</sup>Ac]Ac-DOTA-TATE in patients that were refractory to [<sup>177</sup>Lu]Lu-DOTA-TATE. Herein, we report the radiosynthesis, toxicity, biodistribution (BD), radiation dosimetry (RD), and efficacy of [<sup>225</sup>Ac]Ac-DOTA-TATE in small animal models of lung neuroendocrine neoplasms (NENs).<h4>Methods</h4>[<sup>225</sup>Ac]Ac"],"journal":["European journal of nuclear medicine and molecular imaging"],"pubmed_title":["Preclinical evaluation of [&lt;sup&gt;225&lt;/sup&gt;Ac]Ac-DOTA-TATE for treatment of lung neuroendocrine neoplasms."],"pmcid":["PMC12866175"],"funding_grant_id":["P30-CA076292","P30 CA076292"],"pubmed_authors":["Tichacek CJ","El-Haddad G","Ji H","Chiappori AA","Pandya DN","Strosberg JR","Budzevich MM","Boulware DC","Engelman RW","Tafreshi NK","Reff JN","Wadas TJ","Wang Z","Morse DL"],"additional_accession":[]},"is_claimable":false,"name":"Preclinical evaluation of [&lt;sup&gt;225&lt;/sup&gt;Ac]Ac-DOTA-TATE for treatment of lung neuroendocrine neoplasms.","description":"<h4>Purpose</h4>There is significant interest in the development of targeted alpha-particle therapies (TATs) for treatment of solid tumors. The metal chelator-peptide conjugate, DOTA-TATE, loaded with the β-particle emitting radionuclide <sup>177</sup>Lu ([<sup>177</sup>Lu]Lu-DOTA-TATE) is now standard care for neuroendocrine tumors that express the somatostatin receptor 2 (SSTR2) target. A recent clinical study demonstrated efficacy of the corresponding [<sup>225</sup>Ac]Ac-DOTA-TATE in patients that were refractory to [<sup>177</sup>Lu]Lu-DOTA-TATE. Herein, we report the radiosynthesis, toxicity, biodistribution (BD), radiation dosimetry (RD), and efficacy of [<sup>225</sup>Ac]Ac-DOTA-TATE in small animal models of lung neuroendocrine neoplasms (NENs).<h4>Methods</h4>[<sup>225</sup>Ac]Ac","dates":{"release":"2021-01-01T00:00:00Z","publication":"2021 Oct","modification":"2026-07-15T07:40:47.693Z","creation":"2026-07-01T03:07:58.317Z"},"accession":"S-EPMC12866175","cross_references":{"pubmed":["33772332"],"doi":["10.1007/s00259-021-05315-1"]}}